IRDOpus Genetics, Inc.
Price
+77%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growth fading, the market undecided.
- BusinessMixed
- SafetyWatch
- Valuationn/a
- GrowthWatch
- MarketMixed
Charts
As reported to the SEC, without any scoring.
Opus Genetics, Inc. (IRD) reported revenue of $755K in Q2 2026 (quarter ended Jun 30, 2026), down 74% from the same quarter a year earlier. That came with net loss of $8.1M. For the full year FY2025, revenue was $14M (+29% year on year) and net income −$50M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 21, 2026Opus Genetics, Inc. (the “Company”) and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company’s Chief Scientific and Development Officer, effective as of October 19, 2026 (the “Separation Date”)Director or officer change · Form 8-K
- Oct 15, 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026.Regulation FD disclosure · press release
- Sep 11, 2026OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.